ALSO NOTED: New River inks new licensing deal; Panacea nails $7M round; Miravant CEO resigns; and much more...

> New River Pharmaceuticals has entered into a licensing deal with the Ernest Gallo Clinic and Research Center at the University of California San Francisco to investigate a new approach toward improving the use of opioid analgesics in the treatment of pain by reducing the development of tolerance. Release

> Panacea Pharmaceuticals of Gaithersburg, Maryland, has raised $7 million in its third round. Mitsubishi Corporation Life Sciences Venture, Olympus, JSR, Shin-Etsu Chemical, Fuji Photo Film, Dai Nippon Printing, and Tokio Marine & Nichido Fire Insurance all participated. Release 

> Dutch biotech Pepscan Systems has raised $6 million in its first round. Release

> Chutes & Ladders: Gary S. Kledzik, PhD, CEO, chairman and director of Miravant Medical Technologies of Santa Barabra, California, has resigned. Release

> A new study from researchers at Columbia University says that prescription drug abuse in the US has hit epidemic proportions, with more than 15 million people -- including 2.3 million teenagers -- abusing pharmaceuticals. Story

And Finally... New York City health officials plan to monitor how well diabetics manage their ailment. Story

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.